» Articles » PMID: 23709659

Risk Factors for Adverse Outcomes by Left Ventricular Ejection Fraction in a Contemporary Heart Failure Population

Overview
Journal Circ Heart Fail
Date 2013 May 28
PMID 23709659
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although heart failure (HF) is a syndrome with important differences in response to therapy by left ventricular ejection fraction (LVEF), existing risk stratification models typically group all HF patients together. The relative importance of common predictor variables for important clinical outcomes across strata of LVEF is relatively unknown.

Methods And Results: We identified all members with HF between 2005 and 2008 from 4 integrated healthcare systems in the Cardiovascular Research Network. LVEF was categorized as preserved (LVEF ≥ 50% or normal), borderline (41%-49% or mildly reduced), and reduced (≤ 40% or moderately to severely reduced). We used Cox regression models to identify independent predictors of death and hospitalization by LVEF category. Among 30094 ambulatory adults with HF, mean age was 74 years and 46% were women. LVEF was preserved in 49.5%, borderline in 16.2%, and reduced in 34.3% of patients. During a median follow-up of 1.8 years (interquartile range, 0.8-3.1), 8060 (26.8%) patients died, 8108 (26.9%) were hospitalized for HF, and 20272 (67.4%) were hospitalized for any reason. In multivariable models, nearly all tested covariates performed similarly across LVEF strata for the outcome of death from any cause, as well as for HF-related and all-cause hospitalizations.

Conclusions: We found that in a large, diverse contemporary HF population, risk assessment was strikingly similar across all LVEF categories. These data suggest that, although many HF therapies are uniquely applied to patients with reduced LVEF, individual prognostic factor performance does not seem to be significantly related to level of left ventricular systolic function.

Citing Articles

Prognostic Implications of Insulin Resistance in Heart Failure in Japan.

Iwasaki K, Nakamura K, Akagi S, Takaya Y, Toda H, Miyoshi T Nutrients. 2024; 16(12).

PMID: 38931242 PMC: 11207164. DOI: 10.3390/nu16121888.


Comparative study on the predictive value of TG/HDL-C, TyG and TyG-BMI indices for 5-year mortality in critically ill patients with chronic heart failure: a retrospective study.

Zhou Z, Liu Q, Zheng M, Zuo Z, Zhang G, Shi R Cardiovasc Diabetol. 2024; 23(1):213.

PMID: 38902757 PMC: 11191322. DOI: 10.1186/s12933-024-02308-w.


COVID-19 Prevention and Mitigation Decision-Making Processes While Navigating Chronic Disease Care: Perspectives of Black Adults with Heart Failure and Diabetes.

Johnson L, Josiah Willock R, Simmons S, Moyd S, Geiger D, Ghali J J Racial Ethn Health Disparities. 2024; 12(1):181-190.

PMID: 38702490 PMC: 11531604. DOI: 10.1007/s40615-023-01862-5.


Human immunodeficiency virus infection and risks of morbidity and death in adults with incident heart failure.

Avula H, Ambrosy A, Silverberg M, Reynolds K, Towner W, Hechter R Eur Heart J Open. 2022; 1(3):oeab040.

PMID: 35919879 PMC: 9242035. DOI: 10.1093/ehjopen/oeab040.


Multimorbidity Burden and Incident Heart Failure Among People With and Without HIV: The HIV-HEART Study.

Mefford M, Silverberg M, Leong T, Hechter R, Towner W, Go A Mayo Clin Proc Innov Qual Outcomes. 2022; 6(3):218-227.

PMID: 35539894 PMC: 9079699. DOI: 10.1016/j.mayocpiqo.2022.03.004.


References
1.
Van Veldhuisen D, Linssen G, Jaarsma T, van Gilst W, Hoes A, Tijssen J . B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol. 2013; 61(14):1498-506. DOI: 10.1016/j.jacc.2012.12.044. View

2.
Kalogeropoulos A, Georgiopoulou V, Giamouzis G, Smith A, Agha S, Waheed S . Utility of the Seattle Heart Failure Model in patients with advanced heart failure. J Am Coll Cardiol. 2009; 53(4):334-42. DOI: 10.1016/j.jacc.2008.10.023. View

3.
Go A, Yang J, Gurwitz J, Hsu J, Lane K, Platt R . Comparative effectiveness of different beta-adrenergic antagonists on mortality among adults with heart failure in clinical practice. Arch Intern Med. 2008; 168(22):2415-21. DOI: 10.1001/archinternmed.2008.506. View

4.
Komajda M, Carson P, Hetzel S, McKelvie R, McMurray J, Ptaszynska A . Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail. 2010; 4(1):27-35. DOI: 10.1161/CIRCHEARTFAILURE.109.932996. View

5.
Song E, Lennie T, Moser D . Depressive symptoms increase risk of rehospitalisation in heart failure patients with preserved systolic function. J Clin Nurs. 2009; 18(13):1871-7. PMC: 2742619. DOI: 10.1111/j.1365-2702.2008.02722.x. View